Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.

Gilbert CJ, Gomes T, Mamdani MM, Hellings C, Yao Z, Garg AX, Wald R, Harel Z, Juurlink DN.

Can J Cardiol. 2013 May;29(5):586-91. doi: 10.1016/j.cjca.2013.02.015. Epub 2013 Mar 29.

2.

Combination antihypertensive treatment with aliskiren and blockers of the Renin-Angiotensin system-reassurance but with a note of caution.

Touyz RM.

Can J Cardiol. 2013 May;29(5):521-3. doi: 10.1016/j.cjca.2013.02.020. Epub 2013 Mar 29. No abstract available.

PMID:
23541659
3.

Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study.

Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM.

Arch Intern Med. 2010 Jun 28;170(12):1045-9. doi: 10.1001/archinternmed.2010.142.

PMID:
20585070
4.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators..

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

5.

Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.

Shih CJ, Chen HT, Chao PW, Kuo SC, Li SY, Yang CY, Tarng DC, Ou SM, Chen YT.

J Hypertens. 2016 Mar;34(3):567-74; discussion 575. doi: 10.1097/HJH.0000000000000804.

PMID:
26703918
6.

RAS blockade, hyperkalemia and AKI--look and you will find.

Toto RD.

Nat Rev Nephrol. 2012 May;8(5):257-8. doi: 10.1038/nrneph.2012.62.

PMID:
22473512
7.

Update on role of direct renin inhibitor in diabetic kidney disease.

Dhakarwal P, Agrawal V, Kumar A, Goli KM, Agrawal V.

Ren Fail. 2014 Jul;36(6):963-9. doi: 10.3109/0886022X.2014.900425. Epub 2014 Mar 31. Review.

PMID:
24678880
8.

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.

Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.

Curr Med Res Opin. 2008 Apr;24(4):1039-47. doi: 10.1185/030079908X280581 . Epub 2008 Feb 27.

PMID:
18307835
9.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721. Epub 2009 Jan 14.

PMID:
19145003
10.

Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

Cagnoni F, Njwe CA, Zaninelli A, Ricci AR, Daffra D, D'Ospina A, Preti P, Destro M.

Vasc Health Risk Manag. 2010 Aug 9;6:549-59. Review.

11.

Aliskiren in the treatment of hypertension and organ damage.

Riccioni G.

Cardiovasc Ther. 2011 Feb;29(1):77-87. doi: 10.1111/j.1755-5922.2010.00230.x. Epub 2010 Nov 25. Review.

PMID:
21106033
12.

Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction.

Ozaki Y, Imanishi T, Tanimoto T, Kashiwagi M, Tsujioka H, Sougawa H, Orii M, Shiono Y, Shimamura K, Ishibashi K, Komukai K, Ino Y, Kitabata H, Akasaka T.

Circ J. 2012;76(6):1461-8. Epub 2012 Mar 28.

13.

Direct renin inhibitor induced renal failure.

Vallakati A, Chandra PA, Hollander G, Shani J.

Am J Ther. 2014 Mar-Apr;21(2):e53-5. doi: 10.1097/MJT.0b013e3182459c16.

PMID:
23665882
14.

Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease.

Singh JP, Kulik A, Levin R, Ellinor PT, Ruskin J, Avorn J, Choudhry NK.

Europace. 2012 Sep;14(9):1287-93. doi: 10.1093/europace/eus074. Epub 2012 Apr 26.

PMID:
22539600
15.

An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy.

Tocci G, Aimo G, Caputo D, De Matteis C, Di Napoli T, Granatelli A, Lentini P, Magagna A, Matarrese AA, Perona D, Villa G, Volpe M; DRIVE Investigators..

High Blood Press Cardiovasc Prev. 2012 Jun 1;19(2):73-83. doi: 10.2165/11632170-000000000-00000.

PMID:
22867093
16.

Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.

Zeymer U, Dechend R, Deeg E, Kaiser E, Senges J, Pittrow D, Schmieder R; 3A Registry Investigators..

Int J Clin Pract. 2012 Mar;66(3):251-61. doi: 10.1111/j.1742-1241.2012.02893.x. Epub 2012 Feb 9.

PMID:
22321062
17.

Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.

Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R.

Clin Ther. 2011 Apr;33(4):456-64. doi: 10.1016/j.clinthera.2011.04.011.

PMID:
21635991
18.

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.

Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, Beyene J, Shah PS.

BMJ. 2012 Jan 9;344:e42. doi: 10.1136/bmj.e42. Review.

19.

Recent changes in the landscape of combination RAS blockade.

Epstein BJ, Smith SM, Choksi R.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1373-84. doi: 10.1586/erc.09.127. Review.

PMID:
19900020
20.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Hork√Ĺ K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582

Supplemental Content

Support Center